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RESUMO 
Durante os últimos séculos, o sucesso da medicina moderna tem consistentemente aumentado a 
esperença média de vida da humanidade. Esta maior longevidade é acompanhado por uma 
mudança de paradigma: multimorbidade, causada pela acumulação de doenças relacionadas com 
o envelhecimento, é agora a nossa principal preocupação, ao invés das doenças fatais imediatas 
(por exemplo infeções) do passado. As populações envelhecidas presentemente observadas nos 
países desenvolvidos, já estão a ter repercussões negativas no ideal do estado social e é esperado 
que estas se alastrem para o resto do mundo. A solução científica para este problema assenta em 
desenvolver terapias anti-envelhecimento. 
Nas décadas recentes, o conceito de envelhecimento como um processo biológico fixado foi 
desafiado e indubitavelmente refutado. Atualmente, conhecem-se mais de um milhar de genes 
que modificam a longevidade em organismos modelo, e simples modificações no estilo de vida 
como uma dieta de restrição calórica prolongam a esperança de vida em primatas não-humanos. 
Infelizmente, as descobertas até hoje realizadas estão ainda para ser traduzidas em terapias anti-
envelhecimento com impacto em seres humanos. Neste trabalho nós oferecemos várias 
contribuções científicas para ajudar a mitigar a iminente crise da população envelhecida. 
A nossa contribuição mais proeminente é a criação da base de dados DrugAge 
(http://genomics.senescence.info/drugs/). Este recurso sem paralelo congila sistematicamente 
informação relativa a ensaios de envelhecimento de drogas que aumentaram a longevidade em 
organismos modelo. DrugAge é grátis, está curada manualmente e é composta por 1316 entradas 
representando 418 substâncias diferentes provenientes de estudos conduzidos em 27 organismos 
modelo. Usámos a informação presente na DrugAge para: treinar um algoritmo para estimar o 
potencial anti-envelhecimento de novos compostos; realizar o enriquecimento funcional de 
DrugAge; comparar DrugAge com os genes anti-envelhecimento conhecidos; revelar que género 
não influencia a performance the compostos anti-envelhecimento em organismos modelo. 
Um capítulo independente é dedicado a aplicar a reutilização de drogas para acelerar a descoberta 
de drogas anti-envelhecimento em humanos. Depois de fazer a correspondência entre um meta-
repositório de interações droga-gene e os genes anti-envelhecimento de organismos modelo, 
encontrámos 16 compostos com um considerável potencial para afetar o processo de 
envelhecimento. Duas combinações de drogas são sugeridas para serem testadas em organismos 
modelo.  
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ABSTRACT 
Over the last few centuries, the success of modern medicine has consistently increased the average 
life expectancy of mankind. This extended longevity came a paradigm-shift: multimorbidity is now 
our top concern, instead of the immediate fatal diseases (e.g. infections) of the past. The aged 
populations currently observed in developed countries, are already having negative recursions in 
the social state ideal and are expected to spread to the rest of the world. The scientific solution to 
this predicament lies in developing anti-aging therapies. 
In the recent decades, the idea that aging is not a fixed biological process was challenged and 
thoroughly refuted. There are now more than a thousand different genes known to alter lifespan in 
model organisms, and simple lifestyle interventions like a caloric restriction diet prolong the lifespan 
of non-human primates. Unfortunately, the discoveries made so far are yet to be translated into 
meaningful human anti-aging therapies. In this work, we offer several scientific contributions to 
help mitigate the looming aging crisis. 
Our most prominent contribution is the creation of the DrugAge database 
(http://genomics.senescence.info/drugs/). This unparalleled resource systematically compiles 
information regarding drug lifespan assays that increased the lifespan of model organisms. 
DrugAge is free, manually curated and is composed of 1316 entries featuring 418 different 
compounds from studies across 27 model organisms. We used the information provided on 
DrugAge to: train an algorithm for the prediction of the anti-aging potential of new compounds; 
conduct the functional enrichment of DrugAge; compare DrugAge with the known anti-aging genes; 
show that gender does not influence the performance of anti-aging compounds in model 
organisms. 
A separate section is dedicated to applying drug repurposing to accelerate the discovery of anti-
aging drugs in humans. After matching a meta-repository of drug-gene interactions with the known 
anti-aging genes in model organisms, we found 16 drugs with significant potential to affect the 
aging process. Two drug combinations are suggested to be tried in model organisms. 
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1.1. AGING 
The aging phenomenon and its omnipresence in our life lead to us intuitively think that it is a 
“natural part of life” and not much can be done about it. While this might not be true for all 
animals[1]–[6], it surely seemed to be the case with humans. Therefore until recently 
Biogerontology did not enjoy mainstream popularity as an academic discipline. This situation 
changed dramatically when the severe underpinnings of an increasingly older world population 
started to be felt, and scientific progress showed us that the rate at which organisms age is 
everything but set in stone. 
1.1.1. SOCIOECONOMIC PERSPECTIVE 
In developed countries it is clear that humans are living longer[7] (falling mortality rates and 
increased longevity) while reproducing less[8] (falling fertility rate), resulting in population aging. 
Contrary to conventional believe the latter cause seems to be the main driver[9] of population 
aging. Forecasts indicate that population aging is expected to continue[10], [11] and extend 
globally[12]. 
Total fertility rate, calculated as the average number of children per woman implied by current 
women of all ages in a given year, is below the replacement rate of 2.1 for two-thirds of the countries 
(Figure 1.1). 
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Figure 1.1: World map of total fertility rates (2005-2010). From[11]. 
 
An aged population increases the demand for public spending on pensions and healthcare[13], 
calling into question the very foundations of the welfare state and posing a risk of creating inter-
generational conflict. Several policies and approaches have been aimed to address this 
“demographic deficit”[14] (Figure 1.2) such as encouraging increases in the fertility and 
immigration rates[15] and making the population work for longer[9]. 
 
 
Figure 1.2: Organization for Economic Cooperation and Development (OECD) demographic deficit (2000-2030). Observed and 
projected size of the incoming (20–24) and outgoing (60–64) working-age cohorts in OECD countries From [11]. 
16 
 
 
The rise in the total amount of people suffering from illnesses or even disability, caused by the 
increase in longevity[16], is so worrisome and prevalent that it has been termed “epidemic of 
frailty”[17]. The signature of this epidemic is the health status being compromised by complex 
chronic long-term diseases, instead of acute infections. The present work has implications for this 
so-called “chronic disease burden”[18], [19]. 
1.1.2. BIOLOGICAL PERSPECTIVE 
As mention previously, there was a paradigm shift, from the scientific point-of-view, that propelled 
the study of the aging process - Gerontology – to the mainstream of scientific research[20]. This 
turn of event was the discovery that the aging rate is extremely malleable, and it can be exemplified 
by the now classic study headed by Cynthia Kenyon, that showed that a single genetic mutation 
doubled the average lifespan of Caenorhabditis elegans[21]. Since then, several genetic[22], 
pharmacological[23] and lifestyle[24] interventions (Figure 1.3) were discovered to influence 
lifespan drastically in a plethora of distinct model organisms. The volume of scientific research and 
interest was such that a new subfield of gerontology was born – Biogerontology - dedicated primarily 
to achieving healthy old age (extending healthspan) accompanied by improved longevity (increased 
lifespan). 
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Figure 1.3: Rhesus monkey appearance in old age. A and B - Photographs of a typical control animal at 27.6 years of age (about 
the average life span). C and D - Photographs of an age-matched animal on caloric restriction. From [25]. 
 
Although it is easy to empirical distinguish between the phenotype of an adult and senior citizen, 
aging is among the most complex biological processes[26]. Broadly defined, aging is characterized 
by a progressive loss of physiological integrity, leading to impaired function and increased 
vulnerability to death. Worth rephrasing, namely because it goes unnoticed by the general public, 
is the fact that aging is an independent primary risk factor for major human pathologies including 
cancer, diabetes, cardiovascular diseases, and neurodegenerative disorders[27]. 
Biological theories of aging abound[28]–[35], but there is nil consensus over which one of them is 
superior and if even any one of them manages to encapsulate the entire aging-associated 
phenomena[36]. To briefly outline the biological basis of aging we decided to be agnostic in relation 
to biological theories of aging. Instead, we followed the categorization based on the hallmarks of 
aging[27] (but taking into consideration recent results not available to the authors at the time), 
18 
 
which helps to conceptualize its essence and underlying mechanisms in an evidence-based 
manner. 
There are currently nine hallmarks (emphasis on mammalian aging) guiding the biogerontology 
field (Figure 1.4). The hallmarks are treasured from a pragmatic standpoint due to the criteria that 
must be fulfilled in order to be considered a “hallmark” (especially the second and third requisites): 
(i) a hallmark should manifest itself during normal aging; (ii) its experimental aggravation should 
accelerate aging; and (iii) its experimental amelioration should retard the normal aging process 
and, hence, increase healthspan. 
 
 
Figure 1.4: The hallmarks of aging and their functional interconnections. The proposed nine hallmarks of aging are grouped into 
three categories. Top - Those hallmarks considered to be the primary causes of cellular damage. Middle - Those deemed to be 
part of compensatory or antagonistic responses to the damage. These reactions initially mitigate the damage, but eventually, if 
chronic or exacerbated, they become deleterious themselves. Bottom - Integrative hallmarks that are the result of the previous two 
groups of hallmarks and are ultimately responsible for the functional decline associated with aging. From [27]. 
 
Genomic Instability 
The very existence of complex networks of DNA repair mechanisms can only be explained in 
evolutionary terms if the integrity of DNA molecules is continuously challenged throughout life[37]. 
Unfortunately, the genetic lesions are minimized but not completely dealt with, resulting in the slow 
accumulation of genetic damage. 
Premature aging diseases (also called progeroid syndromes), such as Werner syndrome and Bloom 
syndrome, partially resemble normal aging and are the consequence of increased DNA 
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damage[38]. Furthermore, experimental reinforcement or debilitation of DNA repair mechanisms 
delays or accelerates aging, respectively[39]. Of notice ii that in addition to nuclear DNA, 
mitochondrial DNA may contribute to aging, at least in accelerating it[40]. 
Another source of genomic damage is genomic instability caused by defects in the nuclear lamina. 
The nuclear lamina is a dynamical architecture that plays a role in genomic maintenance by 
providing a scaffold for tethering chromatin and protein complexes that regulate genomic stability. 
Not only does nuclear lamina suffers changes in its constitution with normal aging[41], [42], 
mutations in genes associated with it cause accelerated aging syndromes such as the Hutchinson-
Gilford[43], [44] and the Néstor-Guillermo[45] progeria syndromes. 
Telomere Attrition 
Telomeres are the chromosomal regions corresponding to the terminal ends of linear DNA 
molecules. Most mammalian somatic cells do not express telomerase (the only DNA polymerase 
with the capacity to completely replicate telomeres) and telomeres exhaustion ultimately leads to 
their senescence and/or apoptosis[46], [47]. 
In humans, telomerase deficiency is associated with a higher risk of developing diseases that 
involve the loss of the regenerative capacity of different tissues, such as pulmonary fibrosis, 
dyskeratosis congenita and aplastic anemia[48]. 
In model organisms, the causality of telomere length in organismal aging is firmly established, 
genetically modified mice displaying shortened or lengthened telomeres exhibit decreased[49], 
[50] or increased lifespan[51], respectively. 
Epigenetic Alterations 
Similar to genetic instability, epigenetic instability (epigenetic alterations) is so robustly associated 
with aging that the most accurate biological clock is based exclusively on epigenetic marks[52]. 
Among histone modifications, the gene SIRT6 is the most important hallmark in mammals. 
Through histone H3K9 deacetylation it regulates genomic stability, NF-κB signaling and glucose 
homeostasis[53]–[55]. Mutant mice deficient or overexpressing Sirt6, display accelerated aging or 
longer lifespan, respectively. 
Furthermore, gain- and loss-of-function studies have confirmed that transcriptional alterations of 
miRNAs[56] and chromatin alterations[57]–[59] causally modulate aging in invertebrates. 
The attractiveness of the epigenome is that its age-related changes are not irreversible. This 
universe of opportunities for designing anti-aging therapies is already showing promising 
results[60]. 
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Loss of Proteostasis 
Even in the hypothetical condition that the genome was completely error-free, if the mechanisms 
providing quality-control and assurance to the proteome (proteostasis) lose their efficacy with time, 
aging would still occur, with the only difference being that the process would initiate downstream 
of the genome, at the proteome level. Indeed proteostasis is affected by aging[61] and chronic 
expression of aberrant proteins contributes to the development of some age-related pathologies, 
such as Alzheimer’s disease, Parkinson’s and cataracts[62]. 
Two types of biological processes are involved in proteostasis: chaperone-mediated protein folding 
and proteolytic systems; conceptually (in a simplified manner) the first works as a protein quality-
check and repair point and the second as a group of aberrant protein clearance pathways. 
Transgenic flies[63], worms[64] and mice[65] that overexpress chaperones live longer, whereas 
mutant mice deficient in a co-chaperone belonging to the heat-shock family exhibit accelerated 
aging phenotypes[66]. 
Regarding proteolytic systems: chemical inducers of autophagy (autophagy-lysosomal system) 
extend lifespan in yeast[67], flies[68], worms[69], [70] and mice[71], [72]; and increasing 
ubiquitin-proteosome activity is known to extend lifespan in yeast[73] and nematodes[74], [75]. 
Deregulated Nutrient Sensing 
The fact that dietary restriction (Figure 1.3) increases lifespan and/or healthspan in all the 
eukaryote species investigated so far[25], [76], [77] is a statement of the importance of nutrient-
sensing in the aging process. 
The most researched nutrient-sensing pathway is the “insulin and insulin-like grow factor (IGF-1)” 
pathway, which participates in glucose-sensing. An initial observation of its role creates a paradox: 
on the one hand, the activity level of this pathway experiences a decline in aged humans, as well 
as mouse models of premature aging[78]; on the other hand further attenuation of its signaling 
intensity, through multiple genetic interventions, in worms, flies and mice robustly prolongs 
lifespan[79]–[81]. The solution lies in considering that these genetic manipulations extend longevity 
because insulin and IGF-1 pathway (IIS) signaling leads to lower rates of cell growth and 
metabolism, hence culminating in lower rates of cell damage; and assuming that, for the same 
reason, aged organisms naturally decrease IIS activity in an attempt to maximize survival. It would 
logically follow that minimizing IIS activity would maximize lifespan in the same proportion. 
However, this is contradicted by evidence. In reality, low but not extremely low levels of IIS signaling 
are optimal for an aged organism[82]. 
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Another intensively studied nutrient-sensing system is the mammalian target-of-rapamycin (mTOR), 
and it senses amino-acid concentrations. Genetic downregulation of mTORC1 (one of the 
complexes of which mTOR kinase is part of) extends lifespan in several model organisms[83], [84]. 
What’s more, rapamycin is considered the most robust lifespan-extending pharmacological 
intervention in mammals[85]. 
Mitochondrial Dysfunction 
It is no surprise that the classical theory of aging – the mitochondrial theory of aging[86] – finds a 
culprit in mitochondria if we note that: life is based on energy flow, and the cellular “power plants” 
are the mitochondria; it is known that their efficacy diminishes with aging[87]. 
The mitochondrial theory of aging proposes that global cellular damage is the consequence of a 
positive feedback loop between mitochondrial dysfunction and production of reactive oxygen 
species. The suggested paradigm was recently superseded by the mitohormesis concept, 
supported by experimental evidence showing that increased production of reactive oxygen species 
prolongs lifespan[88]–[91] in model organism instead of accelerating aging and that antioxidants 
fail to extend lifespan[92], [93]. 
The mitohormesis paradigm states that mild exposure to toxic factors triggers defensive responses 
that end up overcompensating for the damage, resulting in a superior cellular fitness in the pos- 
versus pre-exposure states[94]. 
Cellular Senescence 
The amount of senescent cells (cells exhibiting irreversible cell cycle arrest coupled to stereotyped 
phenotypic changes) increases with aging[95]. It is not known if this accumulation is due to an 
increased rate of generation of senescent cells and/or a decrease in their rate of clearance. 
Nonetheless, new evidence unambiguously establishes a causal link between the aging phenotype 
and senescence cell population size[96]. 
The belief in the potential of directly targeting cellular senescence as an anti-aging intervention is 
exemplified by the definition and exploration of a new functional class of drugs termed 
senolytics[97]. 
Stem Cells Exhaustion 
Adult organisms retain several stem cell niches that are responsible for tissue regeneration 
throughout their lifetime. 
22 
 
Almost by definition, the regenerative potential of tissues diminishes with aging. Experimentally, it 
is found that functional attrition of stem cells is ubiquitous across cell populations[98]–[100]. 
Although the deficient proliferation of stem cells is detrimental to healthy aging, an excessive 
proliferation rate, which translates into niche depletion, leads to premature aging in flies[101]. 
Parabiosis experiments, in which and old and young mice share one circulatory system, have 
shown that the old mice experience a reversal in stem cell functional decline coupled with increased 
health- and lifespan[102], consistent with the view of stem cells exhaustion as an integrated 
hallmark. This experimental evidence suggests that stem cell rejuvenation therapies might be 
feasible and with benefic repercussions at the organism level[103]. 
Altered Intercellular Communications 
Aging-associated changes are present not only at the individual cell level but also on how cells, 
tissues, and organs interact with one another. Altered intercellular communications are the most 
holistic hallmark of aging. An old cell might communicate differently with its neighbors and the 
aggregated effect of miscommunicating aged cells is the general deregulation of neurohormonal 
signaling characteristic of aged organisms. 
Among the types of aging-associated changes in intercellular communications, one can count 
chronic inflammation[104] and immunosenescence[105], but from a therapeutic perspective the 
most interesting is, arguably, “contagious aging”. 
Contagious aging is the spatial propagation of aging, in which an aged cell, tissue or organ, leads 
to aging-specific deterioration of another cell, tissue or organ. For example, senescent cells induce 
senescence in neighbor cells via chemical signaling[106].  Therapeutic significance does not lie in 
contagious aging per se, but instead in the experimental validation of its corollary consisting in the 
inversion of the concept; in other words, anti-aging interventions targeting a particular tissue can 
have the side-effect of slowing or halting the aging process in other tissues[51], [107]. 
1.1.3. ANTI-AGING THERAPIES 
Lifespan-extending interventions can be one of three natures: pharmaceutical; genetic; or lifestyle 
modification. 
The main lifestyles changes that are shown to increase healthspan or thought to extend lifespan 
are physical exercise and dietary modifications, namely caloric restriction (Figure 1.3). 
Physical exercise does not extend lifespan, but it improves healthspan[108]. Exercising guidelines 
have long been a recommendation of health-concerned organizations from all over the world, and 
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rightly so[109]. Nonetheless, exercise alone cannot make up for the modern society lifestyle. The 
increasingly sedentary lifestyle negates or attenuates many of the health benefits conferred from 
physical exercising, independently of the physical activity level (exercise intensity)[110]. 
A calorie restricted diet, which consists in reducing the daily caloric intake by up to 40%, 
consistently extends healthspan and lifespan in many model organisms[111] and improves 
diseases risk factors in humans[112]. Unfortunately, its benefits of delaying the majority of age-
associated diseases come at the price of disrupting the homeostatic state of the adult human body, 
for example, it leads to menstrual irregularities, loss of libido and slower wound healing[113]. The 
clear failure in translating the potential of caloric restriction to humans resulted in two refinements 
of the concept: fasting-mimicking diets and caloric restriction mimetics. 
Fasting-mimicking diets aim to maximize the upsides and minimize the side-effects of purely 
restricting calories, by imposing their limitation in the time domain. They come in the form of: time-
restricted feeding, which imposes a daily time window for the feeding period; intermittent fasting, 
which features ad libitum days followed by days without food or with a very low-calorie daily intake; 
or cycling relatively extended periods of normal dieting and calorie restricted dieting[114]. The 
initial results of fasting-mimicking diets do seem to improve the applicability of the caloric restriction 
concept to humans[115], although only studies using cohorts of small sizes are available. Another 
limiting factor in using fasting-mimicking diets as anti-aging interventions is that due to their 
multifactorial nature many variables still need to be optimized and tailored to special populations. 
As a case in point, old mice are negatively affected by a 4-day mimicking-fasting diet, but not by 
the same diet when this is restricted to just three days[116]. 
Caloric restriction mimetics[117] are small compounds that when ingested trigger phenotypic 
changes akin to the ones elicited by following a calorie restricted diet. The ultimate goal is to design 
a pill that would be taken daily by anyone and improve the healthspan and lifespan of the individual, 
akin to the canonical anti-aging miracle pill. 
The mere existence of research focused on finding caloric restriction mimetics as a perfection of a 
calorie restricted diet brings to surface two crucial facts: that there is enough evidence suggesting 
that such compounds might actually exist (otherwise we would not see any scientific endeavor on 
this facet, especially since alternatives, like fasting-mimicking diets, are showing promising results); 
and that pharmacological interventions are more desired than their lifespan modification 
counterparts (in which poor compliance is a common issue). 
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More than a thousand genetic interventions are known to result in lifespan extension of model 
organisms[22]. However, this otherwise mighty potential is betrayed by the ethical and technical 
challenges associated with the application of gene therapy in humans. The ethical factor (notice 
that we are referring to intervention in adult humans and not germline editions) is a limitation 
secondary to the technical challenges. If there were no safety issues with gene therapy, we believe 
that gene therapy would become widely adopted and even ordinary. 
In the technical front, the discovery of the CRISPR technology, the technology with the fastest 
adoption rate in history[118], is revolutionizing gene therapy. It does so because it is cheaper, 
highly-customizable (due its modular structure) and more efficient in gene editing (including knock-
ins) than the competing techniques. As a potential anti-aging intervention, it could be used to target 
the genome and epigenome[119], and be administered by gene vectors or to stem cells that would 
then be transplanted into the patient[120]. 
The unprecedented rate of progress of the CRISPR technology has not yet arrived at the point in 
which the rate of off-target mutations is not larger than the rate of spontaneous mutation in the 
human genome. Until then, the usefulness of gene therapy for anti-aging interventions remains at 
a distance. 
The last type of anti-aging intervention left to discuss is pharmacological interventions. 
For virtually every single chronic disease for which an oral pharmaceutical treatment is viable, they 
are the option of choice. The hassle-free administration mode allows the patient to adhere to the 
doctor’s orders, maximizing the success of the treatment. 
For the first time in humanity’s history there exists enough scientific knowledge and evidence to 
support an anti-aging clinical trial. This pioneer clinical trial is not the fruit of chance but a 
culmination of years of dedication in fighting aging. 
Several years ago the National Institutes of Health recognized that aging could be targeted and 
established the National Institute of Aging Interventions Testing Program.(ITP) This program is 
conducted at multiple centers and tests potential anti-aging interventions in genetically 
heterogeneous (outbred) mice. After its successful results in ITP, metformin is now going to be 
subjected to a randomized, controlled clinical trial[121]. 
Even though the landscape of aging research provides reasons for being optimistic, it is worth 
noticing that metformin is just a single compound, and a single compound intervention is always 
theoretically suboptimal in manipulating a multifactorial process such as aging. Biogerontologists 
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are well aware of this short-coming and are searching and exploring other potential life-extending 
compounds[122]. 
1.2. MACHINE LEARNING 
The human brain is a fascinating organ. Through millions of years of evolution, it became expert in 
pattern recognition, abstract thinking, and language[123]. Unfortunately, its organic nature sets 
rigid limitations in the volume of information that it can process[124] and makes it only adept to 
the simplistic modeling of the world[125]. 
The alternative that bypasses the constraint of an organic computational architecture is to use 
computers to store information and appropriately extract meaningful knowledge from it, or, in one 
word, to learn. Machine learning is the field of study that is centered in giving computers the ability 
to learn without being explicitly programmed by static instructions[126]. The learning capabilities 
of machine learning applications have benefited greatly from Moore’s law and progresses in applied 
mathematics, statistics, and computer science. They are the only available avenue for inference in 
highly nonlinear systems of unprecedented scale exhibiting a rich landscape of interactions[127]. 
1.2.1. CLASSIFICATION TASK 
The tasks that machine learning is applied to can be categorized accordingly to the type of output 
desired from the machine-learned system. The task faced in the current work is called 
classification, and it consists of the model outputting a class label given an example as input. In 
our case, we will be doing binary classification since there are only two possible classes that a 
given sample instance can be assign to: or it belongs to group X or it doesn’t. 
An additional way of categorizing machine learning tasks is based on the nature of the learning 
“signal” or “feedback” available to the learning system[128]. Categorized in this way our binary 
classification task belongs to the “supervised learning” realm. It does so because we are going to 
use labeled examples to teach the learning system a mapping of their features to their class 
memberships. 
An interesting concept useful in a classification task, and that we are going to take advantage of is 
to program the learning system to output not only the class label that it classifies a given sample 
to belong to but the probability of it belonging to each of the available classes. For example, a 
system trained to predict the gender of a person by using as input the individuals' height, instead 
of outputting just “Male” or “Female”, it would output “0.35 chance of Male and 0.65 of Female”. 
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The last type of output is usually referred to as “class probabilities” and it reflects the degree of 
confidence with which the system classified each sample. 
1.2.2. ALGORITHMS 
A machine learning algorithm can be loosely defined as the set of formalized instructions that one 
takes to build a machine learning system. 
There are thousands of algorithms available to choose from, so the choice should be tailored to 
the specific problem and objectives at hand. For our binary classification task, we seek an algorithm 
capable of state-of-art performance in datasets of similar nature to ours. Ideally, it should also 
naturally output class probabilities. As it turned out, our classification task has two additional 
special traits that need to be taken into consideration: the existence of class imbalance and the 
fact that the number of predictors far exceeds the number of observations available to train the 
algorithm. 
Our dataset is class imbalanced because one of the classes as significantly more samples than the 
other. If a static rule that outputted the majority class label independently of the input sample were 
created, it would achieve an accuracy proportional to the class imbalance of the dataset without 
actually doing any learning. The disregard for class imbalance might lead to use algorithms that 
bias toward the majority class, in other words, they fail to predict the minority class. In our case, 
this consideration has additional weight since the minority class is the targeted class of interest. 
When the number of predictors is much larger than the number of samples (also called “� ≫ �”) 
we are dealing with a high-dimensional dataset[129]. The danger is that there are more ways to 
separate data samples (subset the high-dimensional sample space) than there are samples. In this 
setting the algorithms overfit (find ways to explain the noise of the data), losing generalization 
capabilities. 
Random Forest 
Taking into consideration the characteristics of our dataset, we choose to base our classifier on the 
random forest algorithm[130]. 
It is called “forest” because its outputted prediction results from the aggregation (e.g. using the 
majority vote or the average of class probabilities) of the output of several independent instances 
of a decision tree algorithm (Figure 1.5). The “random” part originates from the fact that each 
decision tree only as access to a random fraction of the available data[130]. This source of 
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randomness gives “biodiversity” to the forest and therefore it is also the source of the robustness 
of the random forest algorithm. 
 
 
Figure 1.5: Decision tree. A decision tree is a hierarchical structure and the basic unit of the random forest algorithm. Each 
internal node stores a split (or test) function to be applied to the incoming data. Each leaf stores the ﬁnal answer (predictor). Here 
we show an illustrative decision tree used to ﬁgure out whether a photo represents an indoor or outdoor scene. From [131]. 
 
Notice that because the decision trees are grown independently, with only the aggregation step 
requiring information from all of them, the random forest algorithm is renowned for its scaling 
properties. 
Random forest can handle binary/categorical and continuous input features simultaneously since 
all types of inputs are easily partitioned by a decision tree (anything can be converted into a binary 
logic test). 
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Ensemble learners, that is methods that are based on the aggregation of many independent 
classifiers, and, more particularly, random forests hold the state of art results in high-dimensional 
datasets[132], [133]. 
Class imbalance deteriorates the performance of virtually all algorithms[134]. Nonetheless, in a 
large scale comparison of the most popular algorithms in ten imbalanced experimental datasets, 
random forest outperformed all the other models[135]. 
1.3. MOTIVATION AND FRAMEWORK 
The contributions of the present dissertation are discussed in detail in chapters 2 and 3. Although 
they can be read in an almost independent fashion, both are guided by one unifying working 
framework. 
We have commented upon the enormous burdens that aging poses at the population and individual 
levels. We have also enumerated its known underlying biological mechanisms and malleability. 
From the last two statements, we can logically derive the motivation of this work: the aging process 
itself should be the direct target of potential therapeutic interventions. We even go further: aging-
ameliorating interventions should be a top priority of medical research given its unique potential in 
stopping the impending social disaster. 
Allocation of funds to aging-specific research is the fairest among all possible choices of public 
spending in medical research if we consider that, not the majority, but every single member of 
society will directly benefit from it (we will all be old eventually). Furthermore, it is also the choice 
that maximizes return-on-investment, since age is the primary risk for nearly every major cause of 
mortality in developed nations[136]. Lastly, and more important, when people were surveyed about 
if they wished to live longer given that their healthspan would also increase, the result was a 
resounding “yes”[137]. 
The classical paradigm of biomedical research is focused on the treatment of individual diseases. 
This disease-centric tradition as made profound contributions to human health, helping people live 
longer than ever before. However, longer lives without access to successful therapies in preventing, 
ameliorating, or postponing the aging process, culminate, paradoxically, in a longer undesirable 
life stage that continuously accumulates multiple disabilities and morbidities. In lay terms: we are 
living longer, but also dragging out suffering. 
The chosen working framework is grounded on a contrastingly different paradigm: that directly 
targeting and slowing the aging process delays the onset and progression of all aging-related 
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diseases. The clinical importance of this “longevity dividend” cannot be overstated, as even 
maximum success in curing a single chronic illness is insufficient to halt a multimorbidity state 
(and sometimes it even aggravates the other co-morbidities). 
An alternative view of our working paradigm is that it is focused on prevention rather than treatment. 
This hypothesis considers that increasing healthspan (compressing morbidity) is the best choice 
to face the otherwise unmanageable chain of events that cause aging before it even starts. 
We mentioned before that anti-aging genetic interventions have not reached technological maturity 
yet and explained why pharmacological interventions dominate their lifestyle modification analogs, 
therefore therapies of the pharmacological type have the largest likelihood of being adopted post-
haste on a global scale. 
1.4. OBJECTIVES 
Biogerontology’s focus is on efforts to understand, prevent, cure or minimize age-related 
impairments, and the contributions of the current work belong to its domain. 
Working from the framework exposed in the previous subsection, the specific objectives of this 
thesis are: 
Objective 1: Investigate if there are drugs significantly enriched in interactions with human 
homologs of experimentally verified lifespan-extending genes. 
Objective 2: If the answer to Objective 1 is affirmative, prioritize the obtained drugs for further 
lifespan testing in model organisms. 
Objective 3: Create a database dedicated to lifespan assays of drugs known to prolong lifespan 
in model organisms. 
Objective 4: Conduct initial analyses based on the information provided by the database created 
in Objective 3. 
Objective 5: Compile biological and chemical information on drugs that have their lifespan effect 
known in C. elegans, and train and optimize a classifier so that it can be used for readily assessing 
the anti-aging potential of an unexplored compound, in future works. 
1.5. CONTRIBUTIONS 
Motivated by the arguments above and set on the objectives enumerated in the previous sub-
section, we contribute to our field of study in the following ways: 
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Contribution 1: We examined thousands of drugs present in a meta-database of drug-gene 
interactions and found that 16 of them have a significant number of meaningful connections with 
human homologs of model organisms’ lifespan-extending genes. 
Contribution 2: We analyzed the conceptual viability of the top candidate anti-aging drugs and 
ended up suggesting two distinct drug combinations that should be tested in model organisms. 
Contribution 3: We curated almost all the existing literature regarding anti-aging drugs assayed 
in model organisms and present the resulting effort in the form of a new resource: “DrugAge: 
Database of Aging-Related Drugs”. DrugAge is free to use, and it is open to the scrutiny of the 
scientific community at http://genomics.senescence.info/drugs/. 
Contribution 4: We show evidence reinforcing the notion that the more complex an organism is, 
the smaller the relative magnitude of average and maximum lifespan extension achieved by 
pharmaceutical interventions. 
Contribution 5: Through the use of two distinct statistical methodologies we clearly show that, in 
general, sexual dimorphism is not a concerning factor affecting the performance of anti-aging drugs 
in model organisms. 
Contribution 6: We show that there is a statistically significant strong correlation between mean 
lifespan changes and maximum lifespan changes in drug lifespan assays. 
Contribution 7: We contrasted, for the first time, anti-aging interventions of the pharmacological 
and genetic types by comparing the functional analysis and genetic overlap between DrugAge and 
GenAge. 
Contribution 8: We successfully trained and optimized a classifier for gauging the anti-aging 
potentiality of untested chemical compounds. 
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CHAPTER 2: DRUG REPURPOSING FOR AGING 
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2.1. INTRODUCTION 
Having previously mentioned the rationale for the need to tackle the aging process and to ideally 
do so through interventions of the pharmaceutical type, the challenge being considered now is: 
what is the best way to go about it. 
The straightforward approach would be to design de novo drugs specifically targeting the aging 
process. Nonetheless, even assuming that we ignore the complexity and uncertainty wrapping the 
aging process, the drug research and development (R&D) process itself is full of obstacles. 
Even with the rate of technological progress following Moore’s law, bafflingly, every nine years the 
cost of drug development doubles (Figure 2.1)[138]. To make matters more worrisome, this 
increase in the cost of drug development is not compensated by the increase in the number of 
newly approved drugs entering the market. In fact, the latter rate as remained flat since the 
1950s[139]. Such a depressing state of affairs is forecasted to lead to the stagnation of investment 
in drug R&D projects[138]. In actuality, the market sentiment regarding the potential financial 
returns of the pharmaceutical sector is so negative, that the only viable solution relies on the direct 
application of securitization techniques to improve its risk-to-reward profile[140], [141]. 
 
 
Figure 2.1: The number of new drugs approved by the US Food and Drug Administration (FDA) per billion US dollars 
(inflation‑adjusted) spent on R&D has halved roughly every nine years. From [138]. 
 
From a technical perspective, the disappointing results of a candidate drug journey from bench to 
bedside mainly originate from issues with clinical side effects and tolerability[142], [143]. 
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Drug repurposing allows bypassing the drug industry R&D bottlenecks by trying to re-apply 
compounds that were found to be safe and tolerable in human clinical trials to treat health 
conditions that are not their original intended target. Notice that it is of no importance if the drug 
being repurposed was successfully approved for its primary target. As long as it is deemed safe, a 
compound can be subjected to a new therapeutic hypothesis, and its efficacy promptly evaluated 
in a new clinical trial. 
One case of successful drug repurposing is azidothymidine. This compound was deliberately 
developed as an anti-cancer agent and shown to inhibit oncogenic viruses (and tumor 
proliferation)[144]. Failure in treating cancer did not stop it from being approved as an anti-HIV 
therapy, with its previously known antiviral activity convincingly inhibiting HIV replication[145]. 
Two clear advantages are unique to the drug repurposing paradigm: 
 it is a financial free lunch (the investment to develop, register and fully test the compounds 
has already been made) with potential applications only limited by the scientific community 
ingenuity; 
 most of the 17 years period that it takes to translate research findings into clinical 
practice[146] can be skipped by immediately testing the hypothesis at the clinical trial 
stage. 
Compelled by the advantages of the drug repurposing paradigm and inspired by its previous 
achievements, it is the goal of this section to apply a bioinformatics approach to gauge the lifespan-
extension potential of already developed compounds. If compounds with considerable potential are 
to be found, they will be ranked (and therefore prioritized) in an effort of advancing drug repurposing 
in biogerontology. 
2.2. METHODS 
Any drug repurposing project starts by defining the library of compounds to be screened. We find 
an ideal repository of drugs in the Drug-Gene Interaction Database (DGIdb)[147]. DGIdb is the 
largest meta-database of drug-gene interactions, updated weekly, publicly available, and it 
considers information from ongoing clinical trials. Its goal is to “provide users with the most current 
knowledge of clinically actionable drug–gene interactions”[147]. 
Together with using DGIdb as the source of candidate lifespan-extending drugs and their respective 
drug-gene interactions, we also made use of the GenAge Database of Aging-Related Genes[22] to 
gather gene targets for anti-aging therapies. GenAge is also the perfect resource for our purpose 
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because it is the most complete database of genetic interventions that influence lifespan in model 
organisms. 
Version 2.22 of DGIdb was downloaded and imported into RStudio[148] (version 0.99.879) running 
R[149] (version 3.2.3). The base file contained 3158 human genes establishing 29708 interactions 
with 11636 unique compounds. 
Build 18 of GenAge was downloaded and imported into Microsoft Excel 2013. With this step, we 
obtained information regarding 2242 manipulated genes in model organisms. GenAge is a 
repository of genetic experiments that affect lifespan in model organisms, but we are only interested 
in the subset, of 1184 genes, that extend lifespan when intervened upon. Furthermore, it is crucial 
to take into consideration the type of genetic manipulation that when applied to each gene 
culminates in lifespan extension. This consideration subsets the life-extending genes into two 
categories: 
 One group of lifespan-extending GenAge genes which increase longevity when they are 
knockdown or knockout (reduced levels of gene expression) and are called “anti-longevity” 
genes; 
 Another group of genes which only prolongs lifespan when they are over-expressed or 
knock-in (increased gene activity) and are defined as “pro-longevity” genes. 
After data cleaning, we found 988 and 175, anti-and pro-longevity lifespan-extending animal genes, 
respectively. 
We used the dbOrtho web service of bioDbnet[150] (version 2.1) to convert the two subsets of 
GenAge lifespan-prolonging genes into human orthologues. The two resulting subsets of 995 and 
198 unique human orthologues were then imported to RStudio. Due to the orthologue conversion 
58 genes were common to both subsets of human genes and removed as their nature as anti- or 
pro-longevity is ambiguous. Of our 1077 total non-redundant human orthologues of GenAge 
lifespan-extending genes, 140 were pro-longevity genes and 937 were anti-longevity genes. 
Of the 1077 non-redundant human orthologues, 357 (59 and 298, pro- and anti-longevity genes 
respectively) were present in DGIdb, interacting with 2064 distinct drugs. 
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Table 2.1: Categorization of DGIdb´s drug-gene interactions according to their effect on gene expression levels. 
Anti Neutral Pro 
antagonist n/a activator 
antagonist, antibody binder agonist 
antagonist, inhibitor modulator agonist, modulator 
antagonist, inhibitor, competitive antibody agonist, partial agonist 
antagonist, inhibitory allosteric modulator other/unknown chaperone 
antagonist, multitarget allosteric modulator cofactor 
Antisense multitarget inducer 
antisense oligonucleotide ligand partial agonist 
binder, antagonist agonist, antagonist partial agonist, agonist 
Blocker antagonist, partial agonist potentiator 
Cleavage vaccine product of 
competitive, inhibitor adduct stimulator 
Inhibitor partial agonist, antagonist   
inhibitor, antagonist immunotherapy 
inhibitor, competitive antagonist, agonist 
inhibitory allosteric modulator positive allosteric modulator 
inverse agonist agonist, inhibitor 
multitarget, antagonist   
negative modulator 
partial antagonist 
Suppressor 
 
Previously we made the distinction between pro-longevity and anti-longevity genes. This distinction 
is relevant now that we have gathered all the gene interactions because it is time to select the ones 
that we can assume that would influence lifespan. 
A drug that inhibits pro-longevity gene is not expected to extend lifespan because this interaction 
would only be meaningful (for our purposes) if it was an interaction that would increase the 
expression of the gene. Several other possible cases of drug-gene interaction could be considered 
with the variables being the nature of a longevity gene (anti or pro) and the type of interaction 
between a drug and that gene. In order to focus exclusively on the drug-gene interactions that 
prolong lifespan we assigned all sorts of drug-gene interactions present in DGIdb to the 
categories ( 
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Table 2.11): 
 “Anti” - types of drug-gene interactions that might extend lifespan if an anti-longevity gene 
is being considered; 
 “Pro” - interactions that increase gene expression (or similar magnification of gene 
influence) and therefore should be taken into account when we are dealing with a pro-
longevity gene; 
 “Neutral” - interactions that couldn’t be included in neither of the other categories because 
they are ambiguous (case-specific) or non-informative. 
Some of the cases related to some interaction types were manually checked to assure the quality 
of our analysis. Of these 2064 drugs, only 489 had interactions in a meaningful way, that is, the 
interaction type was the required for a specific gene to exert its anti-aging effects. 
 
Table 2.2: Summary of the 16 chemical compounds found to be significantly enriched. 
Drug Primary Name AdjPvalue SuccSample FailSample SuccPop FailPop 
Dacinostat 7.07E-13 10 0 98 3050 
Givinostat 7.07E-13 10 0 98 3050 
Abexinostat 7.07E-13 10 0 98 3050 
Belinostat 7.51E-12 10 1 98 3049 
Vorinostat 7.51E-12 10 1 98 3049 
Pivanex 7.01E-10 8 0 100 3050 
Sodium phenylbutyrate 7.01E-10 8 0 100 3050 
Panobinostat 2.42E-08 10 8 98 3042 
Valproic acid 3.18E-07 10 12 98 3038 
Romidepsin 2.05E-05 5 0 103 3050 
CHR-3996 6.21E-04 4 0 104 3050 
Roflumilast 6.21E-04 4 0 104 3050 
Entinostat 3.01E-03 4 1 104 3049 
Ipatasertib 1.85E-02 3 0 105 3050 
MK2206 1.85E-02 3 0 105 3050 
Ibudilast 1.98E-02 4 3 104 3047 
 
Next, we measured the statistical enrichment of relevant lifespan-extending interaction for each 
drug through the one-sided Fisher’s exact test, using the “exact2x2” R package (version 
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1.4.1)[151] , with null hypothesis being that a drug has the same proportion of interactions with 
lifespan-extending genes (of the type required to prolong lifespan) as the proportion present when 
the entire dataset (DGIdb) is considered. After correcting for multiple hypotheses using Holm’s 
correction[152](� = Ͳ.Ͳͷ), we found 16 compounds significantly enriched in correctly oriented 
directed edges with human orthologues of lifespan-extending GenAge genes (Table 2.2). 
2.3. RESULTS AND DISCUSSION 
The results of the current methodology are part of a manuscript that is currently in the final phase 
of the peer review process for publication in the scientific journal “Human Molecular Genetics”. 
We follow with the analysis and discussion of the results from two perspectives: the drugs obtained, 
and the gerontologic information of the genes by which they exert their effects. It is our believe that 
the second adds valuable insights to the first, namely in developing a contextualization for the 
expected magnitude of their potential anti-aging clinical effects. 
2.3.1. ENRICHED DRUGS 
A first contemplation of the list of enriched drugs and all of the genes that they target reveals that 
all the implicit drug-gene interactions belong to the anti-longevity category, in other words, the 
candidate compounds shall delay aging solely by inhibiting the expression of anti-longevity genes. 
We do not have any explanation that justifies why pro-longevity drug-gene interactions were not 
enriched. 
We can cluster our statistically enriched drugs into three broad classes accordingly to the lifespan-
extending genes that they target (Table 2.3): 
 histone deacetylases inhibitors (dacinostat, givinostat, abexinostat, belinostat, vorinostat, 
pivanex, sodium phenylbutyrate, panobinostat, valproic acid, romidepsin, CHR-3996, 
entinostat); 
 Akt signaling inhibitors (ipatasertib and MK-2206); 
 phosphodiesterase inhibitors (roflumilast and ibudilast). 
Dacinostat[153] is still an experimental drug, and as yet to reach clinical trials. 
Givinostat has reached the phase II of clinical trials a few times. Unfortunately, it causes 
thrombocytopenia[154], which excludes its application as a candidate anti-aging therapy. 
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Abexinostat is a pan-HDAC inhibitor that mostly targets HDAC1. Its common side effects, which 
include thrombocytopenia, neutropenia, fatigue and anemia[155], do not justify the trade-off 
between quality of life and potential lifespan-extending effects that would be subjacent to its usage. 
 
 
Table 2.3: Enriched drugs and their respective gene targets. 
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ABAT                 X               
AKT1                           X X   
AKT2                           X X   
AKT3                           X X   
HDAC1 X X X X X X X X X X X   X       
HDAC10 X X X X X     X                 
HDAC2 X X X X X X X X X X X   X       
HDAC3 X X X X X X X X X X X   X       
HDAC4 X X X X X X X X X X             
HDAC5 X X X X X X X X X               
HDAC6 X X X X X     X                 
HDAC7 X X X X X X X X X               
HDAC8 X X X X X X X X X X X   X       
HDAC9 X X X X X X X X X               
OGDH                 X               
PDE4A                       X       X 
PDE4B                       X       X 
PDE4C                       X       X 
PDE4D                       X       X 
 
As in the two previous drugs, Belinostat’s clinical side effects (among them one can count anemia, 
thrombocytopenia, dyspnea, and neutropenia[156]) also exclude it as a desirable anti-aging 
intervention. 
Vorinostat is another unattractive candidate anti-aging compound. It causes hematological toxicity, 
mainly in the form of thrombocytopenia[157]. 
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Pivanex is relatively well-tolerated for a compound of the HADC-inhibiting class. Its only side effects 
are nausea and dysgeusia[158]. 
Sodium phenylbutyrate is used to treat urea cycle disorders. It is deemed very safe and tolerable, 
for example, in a phase II clinical study applying it to treat amyotrophic lateral sclerosis it was 
tolerated in all dosages tested (including at a dosage of more than double the suggested therapeutic 
dosage) and histone acetylation was decreased by half[159]. 
Panobinostat is a broad-spectrum HDAC-inhibitor. We disregard its feasibility as an anti-aging 
intervention because it is administered intravenously (which would raise compliance issues) and it 
causes the side effects typical of its functional drug class: thrombocytopenia, fatigue, and 
neutropenia[160]. 
Valproic acid is the outlier in our group of enriched HDAC inhibitors as it also inhibits the OGDH 
(oxoglutarate decarboxylase)[161] and ABAT (4-aminobutyrate aminotransferase)[162], [163] 
genes. It was first approved in 1967 as an anticonvulsive drug and therefore its long-term chronic 
effects are well-studied. Its chronic ingestion leads to significant weight gain and if it were to be 
applied as an anti-aging intervention, platelet, and hepatic functions would have to be closely 
monitored mainly for the risk of thrombocytopenia (which has an incidence of 12%)[164]. 
Romidepsin mostly inhibits HDAC1 and HDAC2. It severely compromises healthspan by causing 
extremely fatigue[165] along with the expected toxicities: nausea, vomiting, fatigue, and transient 
thrombocytopenia and granulocytopenia[166]. 
For the treatment of solid tumors, CHR-3996 display a favorable toxicological profile, but the same 
cannot be said for the treatment of aging, as it caused atrial defibrillation even in the lowest dosage 
in a phase I clinical trial[167]. 
Entinostat is a potent inhibitor of HADC1 and HADC3. Its adverse events reported in several clinical 
trials included anorexia, nausea, hypoalbuminemia, hypophosphatemia, fatigue, headache, 
diarrhea, neutropenia, thrombocytopenia and leukopenia. These are all reversible, but because an 
anti-aging pharmacological intervention is continuous in nature, its toxicological profile is 
unacceptable[168]. 
Ipatasertib is a highly selective pan-Akt inhibitor. It is currently undergoing phase II clinical trials for 
prostate (clinicaltrials.gov NTC01485861) and gastric cancer (clinicaltrials.gov NTC01896531). 
Initial studies seem to indicate that it is relatively well-tolerated for a cancer drug, but it causes 
diarrhea, fatigue and hyperglycemia[169]. 
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MK-2206 is also a highly selective pan-Akt inhibitor and it was the first allosteric small molecule 
inhibitor of Atk to enter clinical development[170]. It has and still is being tested in multiple phases 
I and II clinical trials. Rashes tend to be the only reported common side effect and are observed in 
a dose-dependent manner[171]. 
Roflumilast is a highly selective phosphodiesterase-4 inhibitor approved for the treatment of chronic 
obstructive pulmonary disease. In contrast to the majority of drugs for treating chronic obstructive 
pulmonary disease, it is not inhaled but instead taken orally, a once a day. The only clinical side 
effects observed with its administration are diarrhea (in a few instances leading to hospitalization) 
and weight loss (an average of 2kg and more relevant in obese patients)[172], [173]. The intestinal 
distress might be attenuated by the titration of the dose up to the recommended dosage[174]. 
In Japan, ibudilast has been approved as a daily treatment of asthma for more than two decades. 
It is a non-selective phosphodiesterase inhibitor, and therefore it causes moderate gastrointestinal 
adverse effects. However, it should be noted that this is the only common side-effect and that it 
disappears after 2-4 days[175]. Highly encouraging and emphasizing its safety and tolerability is 
the fact that in a recent systematic study of drug repurposing for secondary progressive multiple 
sclerosis (a disease requiring long-term treatment, just like in anti-aging therapies) ibudilast was 
one of the few selected lead candidates for clinical evaluation[176]. 
2.3.2. BIOGERONTOLOGY OF THE TARGETED GENES 
4-aminobutyrate aminotransferase 
The 4-aminobutyrate gene is a newly aging-associated gene, and therefore its role in aging is still 
unknown. Its deletion in yeast extends mean chronological lifespan by 15-50%[177]. 
AKT serine/threonine kinases 
The AKT serine/threonine kinase 1 (AKT1) gene isoform was studied in several human genome-
wide association studies. In Caucasian populations the results are mixed, some studies find SNPs 
in AKT1 significantly associated with longevity[178]–[180], while others do not[181]–[183]. In a 
Han Chinese population, two AKT1 haplotypes were significantly represented in long-lived 
individuals[184]. 
Haploinsufficiency of Akt1 (the mouse homolog of AKT1) extends mean lifespan by 8% in males 
and 15% in females when compared to wild-type. The mutant mice had the same weight but less 
body fat. In C. elegans, the same studied reported that inhibition of akt1 (the worm homolog of 
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AKT1 and AKT3 isoforms) extends lifespan[185], which is consistent with previous literature that 
also used RNA interference to inhibit akt1[186]. 
Deletion of Saccharomyces cerevisiae’s SCH9 (the yeast orthologue of all the three AKT human 
isoforms) more than triples its mean chronological lifespan[187]–[189]. 
It must be mention that, contrary to what the deletion experiments in yeast might suggest, maximal 
reduction of AKT expression should not be a therapeutic goal as AKt1, AKt2 or AKt3 null mice are 
all viable but display severely compromised healthspan[190], [191]. 
Histone deacetylases 
The human HDAC1 gene has a homolog in the gene Rpd3 of D. melanogaster. A decrease in Rpd3 
gene expression mimics caloric restriction, and there is sexual dimorphism in the magnitude of 
lifespan extension that it induces. Males heterozygous for hypomorphic or null mutation of Rpd3 
have a lifespan extension of 33% and 41-47%, respectively. While females heterozygous for a 
hypomorphic allele have a 52% increase in lifespan, and those carrying a null mutation, do not 
display median lifespan extension.[192] 
In yeast, there are two homologs of human HDAC genes: HDA1 is a homolog of HDAC4, HDAC5, 
HDAC6, HDAC7 and HDAC9; and RPD3 is a homolog of HDAC2, HDAC3, and HDAC8. Only the 
HDAC1 is considered to be a homolog of both of the yeast genes.  
Deletion of RPD3 extends replicative lifespan by 41%[193], [194] and, corroborating the results 
obtained in flies; there was no additive effect with caloric restriction. Deletion of HDA1 has no 
effect[194] or a very moderate one[67] of its own on longevity but acts synergistically with caloric 
restriction to increase life span. 
Oxoglutarate dehydrogenase 
The human oxoglutarate dehydrogenase gene (OGDH) is a homolog of the C. elegans, S. cerevisiae, 
and S. pombe; odgh-1, KGD1, and SPBC3H7.03c genes, respectively. 
In worms, RNA interference of odgh-1 extended lifespan by 79%[195], a result congruent with the 
increase in lifespan observed when SPBC3H7.03c suffers deletion in fission yeast[196]. Curiously, 
in baker’s yeast, KGD1 deletion halves the lifespan in two different studies[177], [197]. 
Phosphodiesterase 4 isoforms 
All the four human phosphodiesterase isoforms (PDE4A, PDE4B, PDE4C, and PDE4D) have the 
dunce gene of D. melanogaster as a homolog. Cyclic adenosine monophosphate 
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phosphodiesterase-deficient dunce mutants enjoyed a maximum lifespan extension of about 
70%[198]. 
2.3.3. RECOMMENDED DRUG COMBINATIONS 
Aging is a multifactorial debilitation, even at the genetic level, so it makes sense that a 
pharmaceutical intervention with it as a therapeutic target should benefit from a composite set of 
drugs that individually target each of its contributing factors. 
We can attempt to suggest combinations of this kind based on the targets of our enriched drugs 
(Table 2.3) and their side effects. These combinations can then be tested in model organisms and 
evaluated using lifespan and healthspan endpoints. 
We shall give priority to tolerability and safety criterions for two reasons: the lifespan-extending 
effects of the obtained drugs are still unknown, and so they cannot be taken into consideration; 
and that for an intervention that it is likely going to be chronic, healthspan concerns acquire 
increased importance. 
Of the histone deacetylases inhibitors cluster, sodium phenylbutyrate presents the most attractive 
toxicological profile, and it is our recommendation. 
MK-2206 has, arguably, slightly less unpleasant common side effects (rashes) than ipatasertib 
(which might cause fatigue and hyperglycemia), and, therefore, it is the AKT-inhibitor that we prefer 
for a long-term intervention. 
Both, roflumilast and ibudilast, have a safe history of treating long-term conditions. They also share 
similar toxicological profiles, which imply that either of them could be used for our purposes. 
Of notice, is that two classes of enriched drugs have gastrointestinal distress as a side effect, so 
an addictive aggravation of the same is to be expected when applied to humans (and this will 
probably elude lifespan assays in lower animals). 
In sum, our recommended drug cocktail, targeting lifespan extension without hindering healthspan, 
is composed of sodium phenylbutyrate and MK-2006 plus either roflumilast or ibudilast. Ideally, 
both versions would be experimentally tested. 
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CHAPTER 3: DRUGAGE 
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3.1. INTRODUCTION 
Common sense and the evidence presented in the introductory chapter support the notion that 
pharmaceutical interventions are the preferred type of interventions to ameliorate the aging 
phenotype, which, by its turn, would make it the kind with the potentially widest and fastest 
socioeconomic impact. 
In order to develop an evidence-based anti-aging intervention we naturally started by searching for 
a tool that systematizes the results from drug lifespan assays performed so far. For our surprise 
no such resource existed, and therefore creating one became our priority. 
In the rest of this chapter, we will enumerate the steps taken to create the “DrugAge: Database of 
Ageing-Related Drugs”. DrugAge is a free online resource (available at 
http://genomics.senescence.info/drugs/) driven by feedback from the scientific community. The 
underlying data is the result of an ongoing manual curation effort, with all entries referencing to 
their corresponding PubMed record. The interface is intuitive, fast and responsive. The integration 
of summary tables, clear graphic displays, and annotations using third-party databases allows the 
user to develop additional insights without ever having to leave DrugAge. The database is free to 
download on the website, and we encourage feedback and further data submission. 
We will also analyze and discuss: 
 the statistical analysis of several of the insights that are, for the first time, revealed thanks 
to the wealth of data available in DrugAge; 
 its statistical and functional enrichment analysis; 
 the genetic overlap between DrugAge and GenAge (a database of ageing-related genes); 
 and build a machine learning classifier that estimates the probability of a new compound 
resulting in lifespan extension (namely in C. elegans). 
3.2. STATE OF THE ART 
A biogerontologist looking for genomic information has at his disposal the “Human Ageing Genomic 
Resources”[199]. This online resource integrates information into three freely available databases: 
“GenAge” - a curated database of candidate human ageing-related genes and genes associated 
with longevity and/or aging in model organisms.; “GenDR”[200] - a curated database of genes 
related to dietary restriction in model organisms either from genetic manipulation experiments or 
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gene expression profiling; and “LongevityMap”[201] – a database of human genetic variants 
associated with longevity. 
This wealth of aging-related genetic information is in absolute contrast with the lack of resources 
regarding pharmaceutical assays and longevity, which would leave our not so hypothetical 
biogerontologist to his means, destined to personally mine and curate the hundreds of drug 
lifespan-assays available in the scientific literature. 
One of the first aging-related databases is the Aging Genes and Interventions Database[202].  
However, this resource is largely outdated, which reminds us that a resource that it is not regularly 
maintained and updated to reflect the latest scientific findings is bound to become completely 
useless, and in a relatively short time frame. This crucial insight will be kept with us for the rest of 
this chapter. 
AgeFactDB[203] is a recent meta-database that collects aging factors and their lifespan data 
focusing primarily on the integration of existing aging databases (with the pharmaceutical ones 
being all outdated or abandoned). New data is added to AgeFactDB through automated data-mining 
of research paper abstracts and homology analysis, which although valuable, lacks the confidence 
associated with experimentally validated data. 
We can, therefore, feel the urgent need for aging-related databases dedicated to pharmaceutical 
interventions, which are actively and consistently maintained to a high standard. 
3.2.1. GEROPROTECTORS.ORG 
The youngest aging-related database is “Geroprotectors.org”[23]. It takes special consideration not 
only because the author of this dissertation is one of its co-authors, but mainly due to having been 
developed at the same time as DrugAge and representing an improvement over the aforementioned 
state of the art in many ways. 
Geroprotectors.org is a manually curated database of geroprotectors freely available online 
(http://geroprotectors.org/). A “geroprotector” is any intervention that aims to increase longevity, 
or that reduces, delays or impedes the onset of age-related pathologies by hampering aging-
associated processes, repairing damage or modulating stress resistance. This broad definition 
implies that, for example, magnesium is considered a geroprotector based only on correlational 
evidence, between its dietary intake and mortality in adults at high risk of cardiovascular disease, 
originated from an epidemiological study[204]. The infeasibility of conducting lifespan assays in 
humans means that correlation analyses and interventions that ameliorate biomarkers of aging are 
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preferred, although one cannot scientifically prove that interventions using evidence of this nature 
actually extends human lifespan. 
Although the first database of geroprotectors is of utmost importance for any physician and 
biogerontologist, its focus is distinct from DrugAge. Geroprotectors.org features a wider scope, 
more relevant from a translational/clinical perspective, rather than a pure science paradigm, for 
example, it considers epidemiological studies, clinical trials, drug human approval status, side 
effects and toxicological information. DrugAge, as we will soon see, will focus strictly on compiling 
drug lifespan assays in model organisms and in doing so with the ideal goal of exhaustively 
collecting all the literature available so far. The attempt to fulfill this audacious goal will culminate 
in DrugAge featuring more than double the number of lifespan assays relative to 
Geroprotectors.org. It must also be mention that DrugAge is going to be integrated into the Human 
Ageing Genomic Resources (HAGR), creating a one-stop online resource for biogerontologists’ 
pharmacological and genomic needs. 
A wise scientist will take advantage of the complementarity between the two databases. An ideal 
pharmaceutical intervention would maximize the translational potential of a compound based on 
Geroprotectors.org, with its credibility and expected magnitude of longevity effects based on 
experimental evidence, carried in model organisms, as indicated on DrugAge (and the rest of 
HAGR). Only the full information should be considered a robust indicator of a compound’s feasibility 
to meaningfully extend lifespan and healthspan in humans. 
3.3. TOOLS 
With the current reproducibility crisis overshadowing more than 70% of the scientific results[205], 
it is essential to take deliberate measures to lessen its disgraceful effects. 
Almost all the software used in this thesis is freeware, and the full source code is indiscriminately 
available upon request (requests should be addressed to diogog.barardo@gmail.com). We shall be 
revealing our software choices along the way with the exception of the ClueGO software, which 
demands a longer explanation. 
3.3.1. CLUEGO 
As announced before, we are going to be conducting functional enrichment analyses. A functional 
enrichment analysis consists in two steps. 
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First, we enumerate the biological entities present in our sample and map them to a curated bio-
ontology. A bio-ontology is a schematic that incorporates biological entities into one or several 
concepts (e.g. pathways) and depicts the relation between these concepts[206]. The second step 
is the statistical analysis of the obtained concepts, against a reference background, to check the 
rarity/significance of each of them. 
By far, the largest bio-ontology is Gene Ontology™ (GO)[207]. This ontology is updated daily by the 
Gene Ontology Consortium, which is supported by an open bioinformatics community. Virtually all 
the statistical enrichment analysis software packages are built upon this ontology. The next 
question is: “Which software to choose?”. We continue with the sharing of our experience in this 
regard, which culminates in ClueGO being our tool of choice. The goal is to expose our rationale to 
the scrutiny of the reader. 
Our first choice was to use PANTHER tools[208], which is an online web resource that allows, 
among other analyses, to do functional enrichment analysis. It is actively maintained (an important 
key attribute taking into reflection the high frequency of GO updates) and offers additional 
information based on protein evolutionary clustering (PANTHER™ is an acronym for “Protein 
Analysis Through Evolutionary Relationships”[209]). 
 
 
Figure 3.1: Actual screenshot showing some of the output of PHANTER tools' statistical overrepresentation test analysis of data 
coming from an alpha version of DrugAge. 
 
Figure 3.1 depicts an example of results of an overrepresentation statistical test using PHANTER’s 
“Gene List Analysis” (http://www.pantherdb.org/). The more indentation a GO term has, the 
higher it is located on the hierarchical level; for instance: “protein metabolic process” is a 
subcategory of “primary metabolic process”. We can observe that “cellular process” is a GO term 
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tremendously enriched, and that as it is decomposed into more specific/lower level GO terms, the 
magnitude of the statistical significance decreases. The decline of significance accompanying 
further decomposition is what is expected to happen since fewer elements in a subset imply that 
the p-value range loses granularity. Even in this typical case, we already can appreciate that the 
enriched results should be corrected for a hierarchical structure. Otherwise, the vast majority of 
the strongest enriched terms would be too general to allow any biological insight. 
The need for weighting the structure of the ontology in the enrichment test is even more 
pronounced in the case of the decomposition of “metabolic process” into “nitric oxide biosynthetic 
process”. The top level, “metabolic process”, is more enriched than the second, “nitrogen 
compound metabolic process”, in a typical manner. However, confusion settles in when we 
consider the p-value of the lowest level. It is clearly more significant than its parent, tempting us to 
immediately rationalize that its signal is so strong that it offsets the hierarchical structure bias. 
Such justification would be correct if its significance would be the highest of the decomposition, 
but this is not the case: “metabolic process” still is the term manifesting the highest statistical 
significance. We are now left in a grey zone: the lowest level is more meaningful from an annotation 
standpoint, and considerable enriched (enough to partial offset the hierarchical structure bias), and 
simultaneously, the maximum enrichment is exhibited by the most general term, which is 
uninformative, but shouldn’t be ignored for ad-hoc reasons. The only resource that we found that 
empower us to solve dilemmas of this kind while still using the latest version of GO is ClueGO. 
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Figure 3.2: GO term fusion example. A - The test gene list and the total number of corresponding GO terms. Selection criteria 
applied in ClueGO. B - GO terms selected under the speciﬁed selection criteria. C - Fusion criteria. It applies to GO terms in parent-
child relation, with similar associated genes. The most representative parent or child term is preserved. The terms are organized 
based on their mean level speciﬁcity (up: general terms with low speciﬁcity, down: speciﬁc terms). D - GO terms maintained after 
fusion (colored in blue). Colored arrows show the fusion criteria used (concordance with step C). 
 
ClueGo[210] is a free plug-in for the freeware Cytoscape[211], developed to easily annotate a list 
of genes backed by several distinct ontologies. In our case, we were particularly interested in the 
“GO Term Fusion” feature. This option takes advantage of the stratified nature of GO and uses it 
to remove redundancy through the fusion of related GO terms that have similar genes, namely: the 
terms in parent-child relationship that share similar genes (identical, or with one gene difference) 
are assessed, and the most representative parent or child term is retained (Figure 3.2). Praxis 
show us that GO terms fusion is sufficient to account for the hierarchical noise. 
3.4. CURATION 
The literature mining for DrugAge, which is focus entirely on lifespan-extending compounds, came 
from three sources: freely submitted data by the scientific community and mining of pre-existing 
aging-related databases and PubMed. 
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Among the pre-existing databases that were thoroughly analyzed were: AgeFactDB; 
Geroprotectors.org; and the Aging Genes and Interventions Database. 
We adopted the following search term in the manual mining of PubMed literature: "increases 
lifespan" OR "lifespan increase" OR "lifespan extension" OR "prolongs lifespan" OR "antiaging 
agent" OR "extends lifespan"; and restricted the query to literature published before the year 2016. 
All literature mined was manually curated and subjected to quality-control. Exclusion of research 
papers or some of their assays (partial exclusion) were based on the following criteria: 
 assays without a control group or statistical analysis of the results (exceptions were left to 
the curator’s (the author of this thesis) discretion in order to include some research papers 
that contained information deemed essential for DrugAge, e.g. a large-scale assay; 
 assays that used disease or short-lived strains (relative to the reference strain); 
 lifespan assays based on abnormal diets, e.g. high-fat diets; 
 experiments in which animals were kept in non-standard environmental conditions, e.g. 
high-temperature; 
 experiments that used paper-specific mutant strains, e.g. strains resulting from the 
knockout of one very particular gene; 
 research articles that were not available in the English language; 
 additionally, in the case of data submitted by the community, only data originated from 
research papers indexed by PubMed were considered. 
In the end, data belonging to 325 distinct research articles passed the quality-control stage and 
were therefore included. Efforts were also made to include data that contradicted the purported 
lifespan-extending results already included in DrugAge, with the aim of reflecting the potential 
controversy associated with each compound (although we do not claim an almost exhaustive 
compilation of contrary evidence, as this is not easily defined by search terms). 
DrugAge offers unprecedented scope, comprising 1316 lifespan assays using 418 distinct lifespan-
extending compounds on 27 unique model organisms, including 71 individual strains (Figure 3.3). 
When used in reference to DrugAge data the terms “drug” or “compound” (as we will be doing in 
the next sections) are slightly imprecise. DrugAge includes well-defined chemical compounds such 
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as resveratrol, but also complex substances like apple flesh. The reader is advised to keep such 
consideration in mind. 
3.5. WEB INTERFACE 
DrugAge is freely available at http://genomics.senescence.info/drugs/index.php. From the 
DrugAge home page, some basic search functionality allows the main dataset to be quickly 
accessed and filtered according to keywords e.g. the experimental drug or organism. 
 
 
Figure 3.3: Partial screenshot of the "DrugAge Summary" tab (full page available at 
http://genomics.senescence.info/drugs/visualisation.php). 
 
The user-friendly data browsing interface provides the basic means to search across all DrugAge 
fields and to retrieve drugs based on a range of lifespan effect values. Besides the key experimental 
parameters recorded for each assay, each entry is properly referenced with links to the original 
PubMed record and to any associated GenAge genes that the drug is known to interact with (Figure 
3.4), and a considerable amount of entries even include crucial additional information in the form 
of curator’s (this thesis’ author) annotations (under the “Notes” field). 
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Figure 3.4: Screenshot of a DrugAge browsing experience. 
 
The hyperlinks on the data browser, as depicted in Figure 3.4, also accept specific drugs and 
organisms to be retrieved separately and in more depth, permitting a more detailed investigation 
of the results associated with a specific drug or organism. These pages allow the data to be 
visualized and explored on a per drug or organism basis, such as how species impact on lifespan 
effect for a given drug. 
The contribution of the current thesis’ author in regards to the development of the web interface 
was limited to providing feedback as an alpha- and beta-tester (he played no part in the 
programming of this resource). This subsection is present in this dissertation only for the sake of 
completeness, as we feel that otherwise the full relevance of DrugAge as a scientific resource (and 
therefore the practical value of our contributions) would not be explicitly demonstrated. We invite 
the reader to experience DrugAge personally to discover several unmentioned capabilities, which 
include integration of DGIdb and STITCH drug targets. 
We must quickly mention that in the web interface and for the rest of this section, we will loosely 
use the field/term “average lifespan” to encompass average and median lifespan changes. 
3.6. STATISTICAL ANALYSES 
Under this subsection, we will present exploratory and statistical analyses of the wealth of 
information compiled on DrugAge. When these are based on only a subset of DrugAge, for example, 
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a limited number of species, it is because we excluded the rest of strata due to insufficient sample 
size. 
Our first inquiry was to observe the shape of the distribution of average and maximum lifespan 
changes across distinct model organisms. We found that the magnitude of average life expectancy 
changes per assay is highly species-dependent, and it appears to be inversely correlated with 
organism complexity (Figure 3.5). 
 
 
Figure 3.5: Violin plot based on the average lifespan changes reported on 42 S. cerevisiae, 653 C. elegans, 357 D. melanogaster 
and 63 M. musculus lifespan assays. 
 
The extent of maximum lifespan changes are more modest and not as dissimilar across species 
(Figure 3.6). We could only make use of data referent to three species because this metric is widely 
underreported. 
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Figure 3.6: Violin plot of the maximum lifespan changes obtained in 140 C. elegans, 74 D. melanogaster, and 27 M. musculus 
lifespan assays 
 
In the entire DrugAge, only 326 assays simultaneously reported average and maximum lifespan 
changes. We noted an extremely significant Pearson's product-moment correlation (two-tailed test 
done in R) of around 0.85 (95 percent confidence interval ranged from 0.82 to 0.88), between 
these metrics (Figure 3.7). 
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Figure 3.7: Scatter plot of average lifespan change (horizontal axis) and maximum lifespan change (vertical axis) from assays that 
measured both. Linear correlation p-value < 2.2e-16 (the assumed alternative hypothesis is that true correlation is not equal to 0). 
 
We also focused on assays for males and females, more concretely we used two different statistical 
analysis to determine if gender is a key factor influencing the magnitude of lifespan changes in 
model organisms. 
First, we noticed that two of the species, Mus musculus, and Drosophila melanogaster, have a 
sufficient amount of assays reporting gender-specific average lifespan effects to allow to test if 
exists sexual dimorphism in the general response to a pharmaceutical intervention aimed to extend 
average life expectancy. Using the “dgof” R package, we obtained a p-value of the two-sided 
Kolmogorov-Smirnov test, with the null hypothesis being that the data of both genders originated 
from the same distribution, of 0.9948 and 0.4794, for mice and fly, respectively. Therefore, we 
conclude that sexual dimorphism does not seem to be a significant factor regarding pharmaceutical 
interventions to extend lifespan in Mus musculus or Drosophila melanogaster (Figure 3.8), as the 
distributions of the magnitude of average life expectancy changes are not statically different across 
genders of the two species in consideration. 
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Figure 3.8: Violin plot of the average lifespan change in lifespan assays that displays gender-specific statistics for mice (p-
value>0.99) and flies (p-value>0.47). It aggregates information from 133 and 164 lifespan assays using female and male flies, 
respectively; and from 25 and 30 lifespan assays in female and male mice. 
 
Secondly, we also undertook an alternative analysis of sexual dimorphism by considering data from 
all species in DrugAge and manually curating it so that only lifespan assays that were conducted 
in the same experimental conditions and measured gender-specific endpoints were contemplated. 
This method as the advantage of generating enough data for also assessing the role of gender on 
the magnitude of maximum lifespan changes. Through the application of the same workflow as 
before on curated data obtained from 11 species of model organisms, we obtained statistical 
significant (p-value< ʹ.ʹ × ͳͲ−16) Pearson’s product-moment correlations of approximately 0.88 
(95 percent confidence interval ranging from 0.83 to 0.91) and 0.90 (95 percent confidence 
interval from 0.84 to 0.94) for the magnitude of average and maximum lifespan changes across 
genders, respectively (Figure 3.9). 
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Figure 3.9: Side-by-side display of average (n=140) and maximum (n=65) lifespan changes among gender-paired lifespan assays. 
 
3.7. ENRICHMENT FUNCTIONAL ANALYSES OF DRUGAGE 
In order to discover enriched Gene Ontology terms in targets of compounds in DrugAge, we used 
DGIdb 3 to obtain a list of gene interacting partners for all drugs in DrugAge. To optimize the 
number of hits, we endeavored in manual curation, to ensure that the compound name field in 
DrugAge matched PubChem synonyms. From the set of 418 compounds/substances present in 
DrugAge, 90 were found to have a corresponding record in DGIdb, which translated into 411 
distinct interacting genes composing the genes list that is going to be our input for the statistical 
functional enrichment analysis. 
Statistical functional enrichment analyses require defining a background dataset, which was taken 
as the 3090 distinct Ensembl Gene Ids found in the DGIdb. 
The DrugAge interactors list was passed as input to Cytoscape (version 3.3.0) plug-in ClueGO 
(version 2.2.5) to compute functionally enriched GO Terms. ClueGO used information from all four 
available GO ontologies (08.04.2016) and InterPro (10.04.2016) and matched 3050 entries from 
our background list. We are aware that ClueGO offers other ontologies, including Reactome[212] 
and WikiPathways[213], nonetheless, internal experimentation taught us that the extra annotations 
obtained by selecting these databases (even when we made use of ClueGO’s clustering based on 
GO functional groups) is not enough to compensate for the loss of interpretability (the other 
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databases do not have a hierarchical schema, and therefore the GO term fusion algorithm cannot 
be applied). 
The parameters chosen for the ClueGO analysis were “Use GO Term Fusion” and the entire “GO 
Tree Interval”. We imposed no threshold on the “GO Term/Pathway Selection”. There were 3044 
annotated DrugAge interacting genes. The statistical enrichment was evaluated through a right-
sided mid-P-value hypergeometric test with Bonferroni step-down (Holm-Bonferroni method), 
corrected against the reference set which was the list of DGIdb genes. We decided on this 
background so that our enrichment results reflect DrugAge and not DGIdb, in other words, we 
eliminated the bias that results from having to use DGIdb as an intermediary step in our workflow. 
At the significance threshold chosen (corrected mid-p-value < 0.01), we detected 182 enriched GO 
terms (Table 3.1) out of a universe of 4830 fused GO terms. 
 
Table 3.1: Top-15 enriched GO terms and their statistical significance (corrected mid-p-value). 
GO Term Term statistical significance 
regulation of blood circulation 1.6E-14 
glutathione derivative biosynthetic process 3.4E-14 
blood circulation 1.7E-13 
regulation of system process 2.3E-13 
calcium channel complex 3E-13 
calcium ion transmembrane transport 1.3E-12 
heart contraction 4.1E-12 
glutathione metabolic process 4.7E-12 
voltage-gated calcium channel complex 5.4E-12 
calcium ion transport 1E-11 
regulation of heart contraction 3.7E-11 
inorganic ion transmembrane transport 4.7E-11 
response to xenobiotic stimulus 6.6E-11 
cellular detoxification 6.8E-11 
xenobiotic metabolic process 7.7E-11 
3.8. COMPARATIVE ANALYSIS VERSUS GENAGE 
We also wanted to explore the overlap between DrugAge interacting genes and genes previously 
associated with aging. The rationale behind such analysis is to determine if the known genetic and 
pharmaceutical anti-aging interventions in model organisms, represented by GenAge and DrugAge, 
respectively, are acting upon the same genetic targets. 
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The overlap analysis was based on the 1124 human orthologues of genes that extend lifespan in 
model organisms according to the GenAge database. 
Of the 1124 genes, 287 (25.5%) were known to interact with drugs in DGIdb. Of these, 65 (29.3%) 
were also DrugAge interacting genes (Figure 3.10). 
 
 
Figure 3.10: Venn diagram displaying the number of unique and shared DGIdb genes between DrugAge-interacting genes and 
human orthologues of GenAge lifespan-extending genes. The overlap has 27 more genes than expected by chance. 
 
The statistical overlap between human genes mapped to DrugAge and in GenAge was evaluated 
by Blaker’s Exact Test using the “exact2x2” R package[151]. The background chosen was the set 
of 3090 DGIdb genes. Genes counted as “DrugAge” in Figure 3.10 are all 411 DrugAge-interacting 
genes in DGIdb (originated from the previous subsection). We identified a statistically significant (p-
value= ͸.ͲʹͶ × ͳͲ−6) degree of overlap between the genes arising from the two databases. 
3.9. APPLIED MACHINE LEARNING 
This subsection is dedicated to the training and optimization of random forests for the classification 
of new compounds according to their estimated likelihood of having anti-aging effects. The output 
of our algorithm is going to be class probabilities, and we intend to make use of these as a proxy 
for anti-aging potential. 
A toy example showcasing the usefulness of class probabilities can go as follow: if “compound A” 
is classified as 0.65 likely of being anti-aging (and therefore 0.35 likely of not having anti-aging 
effects) and “compound B” is assigned a 0.90 probability of being an anti-aging substance (and 
hence 0.10 probability of not causing anti-aging outcomes), everything being equal, compound B 
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should be prioritized over compound A for lifespan experiments in model organisms (especially 
Caenorhabditis elegans, for reasons that will become clear later in this subsection). 
To train the classifier, we need a dataset of labeled samples and features that vary among these 
samples. When we were curating the literature for DrugAge, we noticed that the majority of lifespan 
assays belonged to C. elegans and concomitantly started to search the literature for drugs that 
failed to extend lifespan (this includes chemical compounds that have no effect on or decrease 
lifespan) in worms. Our decision to compile a dataset that is based specifically in C. elegans is 
grounded on two considerations: 
 C. elegans has by far the largest representation on DrugAge (Figure 3.3) and it is also the 
only species that we found a considerable amount of compounds that failed to prolong 
lifespan; 
 had we considered the entire DrugAge data; we would have to face the challenge of how 
to select and organize biological features across species, for example, information and 
chemical reactions in a biological pathway might flow differently, contrarily or even be 
inexistent in some model organisms. 
The raw dataset mined from the literature contained 283 anti-aging chemicals and 1272 that did 
not cause lifespan prolongation. The list of compounds was then sent to an external collaborator 
that curated the dataset for redundancy and annotated it for chemical features. The next paragraph 
enumerates the steps taken in the chemoinformatics workflow only succinctly as it is not the area 
of expertise of this thesis’ author. 
The simplified molecular-input line-entry system (SMILES) codes of the drugs were extracted (and 
checked for duplicates) from PubChem[214], [215] and ChemSpider[216], both of which are free 
online chemical repositories. Then the Molecular Operating Environment[217] (MOE), version 
2013v0.8, was used to desalt the chemicals and minimize the structure for the posterior 
calculation of molecular descriptors. Another check for duplicates and errors was done using the 
desalted minimized SMILES outputted by MOE. Chemical descriptors for the compounds were 
calculated from two software MOE and Advanced Chemical Development and any descriptor with 
zero variance or with more than 98% constant values were removed. The chemical curation was 
then considered complete. A dataset comprised of 229 DrugAge drugs that prolong lifespan in C. 
elegans (from here forward denominated as “positive set”) and 1163 compounds that didn’t reveal 
anti-aging effects in worms (henceforth referred to as “negative set”) for which chemical features 
were found was returned to us. 
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In 11 of the 268 chemical descriptors, some drugs (never more than twelve per chemical 
descriptor) had missing values (there were 98 such values in total). Instead of discarding these 
drugs, we decided to proceed with the imputation of these values. To this end, we selected the 
“missForest” R package (version 1.4)[218]. MissForest is a state of the art truly nonparametric 
imputation method that makes no assumptions regarding the data, requires no tuning, avoids the 
need to holdout data for an imputation testing set, is computationally efficient and is capable of 
handling high-order non-linear interactions among variables even in high-dimensional datasets. All 
these impressive characteristics are accomplished in a quite uncomplicated way, as the method 
consists simply in a well-defined algorithm that iteratively repeats two steps: it fits a random forest 
to the observable data, and then it predicts the missing values. The performance of the imputation 
is assessed, for our continuous chemical descriptors, by comparing the absolute difference 
between true imputation error and out-of-bag imputation error estimate in all simulation runs (for 
greater detail, please see the original paper[218]). 
We took care to remove the class membership variable (a categorical feature that reveals whether 
a given drug belongs to the positive or the negative set) of our dataset of drugs from the matrix that 
missForest used as input because we do not want to create an optimistically biased classifier due 
to some information regarding the true class label of the drugs in the testing sets being somehow 
present in the imputed value. When missForest reached the stoppage criterion, the normalized 
mean root square error[219] was less than 0.069. 
The biological features of our dataset were generated in the following way: 
1. We acquired genes that interact with the drugs in the dataset by mining all DGIdb drug-
gene interactions and the drug-protein interactions in the STITCH 4.0 database[220] with 
a confidence score larger than 0.450 (which the authors of STITCH define as confidence 
of medium strength) and limited to only the top-100 protein-drug interactions with the 
highest STITCH confidence score for each compound. This threshold was set in order to 
restrict the influence of the 479 proteins, out of the possible 11352, that were judged 
outliers for having interactions with more than 100 distinct compounds; 
2. We annotated the mined biological drug-interacting entities to GO terms using ClueGO, 
with the same parameters that were used in the enrichment analysis of DrugAge except 
that the background was the built-in Homo sapiens reference set. We decided on using 
human-centered annotations because not only is the GO of C. elegans very poor in 
comparison, but also due to our ultimate objective being the prediction of drugs anti-aging 
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potential in human beings. By mapping drugs to genes/proteins to GO terms, we are 
indirectly bridging drugs and their respective GO terms. Using the GO Term Fusion allows 
diminishing the dimensionality of our final dataset as only non-redundant GO terms are 
going to be considered biological features. 
The 10757 outputted GO terms were interpreted as categorical biological features. We were unable 
to find biological features for all the drugs present in our dataset. Drugs for which no biological 
descriptor could be found were eliminated, with our final dataset consisting of 190 and 783 
compounds belonging to the positive and negative set, respectively. 
Our dataset is imbalanced, but we expect that the actual probability distribution of lifespan-
extending compounds in the known chemical universe to be even more imbalanced. Supporting 
evidence is found in the largest high-throughput assay for lifespan-extending drugs to date (the best 
proxy for the underlying probability distribution currently available). The authors screened 88000 
compounds in C. elegans and found that only 115 extended lifespan[221]. This rarity implies that 
the magnitude of class imbalance properly approximates the real class membership probability 
distribution. 
The algorithm optimization and training were carried using the “mlr” R package (developer version 
2.9), which is a general machine learning interface that works as a wrapper for a plethora of 
learning algorithms available in distinct R packages. We are going to train random forests that the 
mlr package imports from the “ranger” R package[222]. 
We optimized the random forest algorithm for four versions of our dataset: one featuring only 
chemical features; another featuring only biological features; a third version featuring both, 
chemical and biological, types of features; and a fourth version using only chemical features but 
applied to the (larger) dataset of drugs that were present before we discarded the compounds for 
which no biological features could be found. 
The parameters of the random forest algorithm that we tuned were the number of trees in the 
forest and the number of variables to possibly split at in each node (routinely called “mtry” in the 
machine learning field). It is ordinary to tune the number of trees when optimizing a random forest 
algorithm, but tuning the mtry parameter is rare, as a case in point, just one of the articles 
considered in a recent review of the application of the random forest algorithm in the life sciences 
proceeded to do so[223]. We followed the formula to obtain possible parameter values from the 
cited research article[224], which means that three values for the mtry parameter are going to be 
evaluated: the square root of the number of features in the dataset and half and double this value. 
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In setting the number of trees parameter in a random forest there are no consensus or rules-of-
thumb to guide us, therefore, after reading the literature that applied random forests to similar 
classification tasks, we decided to cover a relatively wide range of typical values: {ͳͲͲ,͵ͲͲ,ͷͲͲ,͹ͲͲ,9ͲͲ}. 
We used a nested cross-validation with grid search for tuning. Grid search consists in evaluating 
the performance of every possible configuration of parameters. The nested cross-validation had ten 
folds in each inner loop and ten folds in the outer loop. 
Another crucial aspect in any optimization is deciding on the metric to be optimized. Because there 
is no metric that is superior to all the others; we opted to optimize the algorithms separately for 
three distinct metrics: area under the curve (AUC); F1 measure; and the geometric mean of recall 
and specificity (Gmean). The increased computational cost is more than compensated by having 
three metrics, each capturing distinct components of the performance, guiding our choice of 
parameters. 
Recapitulating, each of the random forests, applied to the four different datasets, for all the 
combinations of values in the optimization grid, was also optimized for each of the three 
performance metrics: AUC, F1 and Gmean. 
We compared the performance of each tested configuration of the random forest algorithm by 
calculating the median rank of the ranked median inner loop out-of-sample performances across 
all 10-folds of the outer loop of the nested cross-validation. 
The summary of the performances obtained for the dataset with only the chemical features and for 
the dataset in which both types of features were used uncontroversially indicate the optimal values 
for the parameters of the random forest algorithm, as there is an agreement for all the different 
metrics utilized as optimization endpoints (Table 3.2). Coincidently, for both datasets, the 
combination of the largest values for each parameter is the one displaying the most robust 
performance. 
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Table 3.2: Performance summary of optimizations run on the dataset with both types of features and on the one that used just 
chemical descriptors. The numbers in a colored background are the relative median rank performances, lower values (greener 
background) are better. Values in colorless background correspond to values taken for the number of trees and mtry parameters. 
In bold and colored blue is the performance of the parameters configuration that we considered best, for each dataset. 
Biological and chemical 
features 
Just the chemical 
features 
AUC 52 105 210 AUC 8 16 33 
100 11,5 12 12,5 100 9 9 7 
300 11,5 8 7 300 11,5 8,5 6 
500 9 5,5 6 500 6,5 8 8 
700 8 4,5 6,5 700 11,5 8 5,5 
900 7 5,5 4,5 900 7 8,5 5,5 
            
Gmean 52 105 210 Gmean 8 16 33 
100 9 7 2,5 100 9 4 5 
300 7,5 4 2 300 4,5 7 3 
500 9 5 2 500 4 5 7,5 
700 9 5 3 700 8 3 4 
900 8 5,5 2 900 4,5 8,5 3 
            
F1 52 105 210 F1 8 16 33 
100 7,5 3,5 3 100 8,5 4,5 5,5 
300 8,5 4 1 300 6,5 7,5 3,5 
500 7 6 3,5 500 4 4,5 8 
700 7 5,5 4 700 9 2,5 5 
900 7 6 3 900 4 7,5 2,5 
 
The situation is not as clear for the dataset that used all drugs (before deleting drugs for which no 
biological features could be obtained) and for the dataset that used only features of the biological 
type (Table 3.3). So much so, that we decided on testing a pair of combinations of values for each 
dataset. 
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Table 3.3: Performance summary of optimizations run on the dataset version with both types of features and on the one that used 
just chemical descriptors. The numbers in a colored background are the relative median rank performances, lower values (greener 
background) are better. Values in colorless background correspond to values taken for the number of trees and mtry parameters. 
In bold and colored blue are the performances of the parameters configurations that we considered superior, for each dataset. 
Just chemical features 
using drugs available 
before deletion 
Just the biological 
features 
AUC 8 16 33 AUC 52 104 207 
100 11,5 4 6 100 6,5 8 11,5 
300 14 6,5 5 300 3 8 11 
500 8 9,5 9 500 5,5 6,5 11,5 
700 10 5 7 700 6 7 11,5 
900 12 5,5 5,5 900 5,5 7 12 
          
Gmean 8 16 33 Gmean 52 104 207 
100 9 2,5 4,5 100 8 3,5 3,5 
300 5,5 8,5 2 300 8,5 5 4 
500 3,5 5 8,5 500 7,5 5 3 
700 8,5 2 4,5 700 8 4 3 
900 6 9 2 900 7,5 4 2,5 
          
F1 8 16 33 F1 52 104 207 
100 9 3 6 100 8 6 2 
300 5,5 9 3 300 8 4 2,5 
500 2 5,5 8 500 7,5 4 3 
700 8,5 2,5 6 700 7 4 3 
900 5,5 9 2,5 900 7,5 3 2,5 
 
The performances of the optimal random forests for each dataset version were contrasted through 
the median AUC in the outer 10-fold cross validation loop (Table 3.4). We opted for optimizing the 
AUC because it is the more commonly reported performance metric in the literature[132]. 
 
Table 3.4: Summary of the performance of random forests optimized for each version of our dataset. In bolded blue is our best 
model. 
Dataset  Number of trees mtry median AUC 
Biological and chemical features 900 210 0.8 
Chemical features before deletion 
100 16 0.781 
700 16 0.774 
Just the biological features 
300 52 0.716 
900 207 0.707 
Just the chemical features 900 33 0.675 
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3.10. DISCUSSION 
The foremost contribution of this section (and thesis) is the creation of DrugAge, a database of 
compounds and drugs experimentally proven to extend average and/or maximum lifespan in model 
organisms. Only compounds, drugs, and substances experimentally shown to extend lifespan in a 
statistically significant manner in at least one experiment were included. Conflicting and negative 
results were then added to provide a balanced literature survey of the effects of each compound 
or drug. 
DrugAge is a freely-available manually curated database offering several tools in an easy browsing 
experience. Its sheer scope and meticulous curation are unmatched, establishing it as a crucial 
resource for the scientific community, which was in great need of a database of anti-aging drugs.  
The practical impact of DrugAge data was demonstrated in the rest of this section, with all the 
analyses and methodologies using DrugAge as an information source. 
Common sense in the gerontology field tells us that the biological complexity of an animal is 
inversely proportional to the relative malleability of its aging phenotype. Actual evidence supporting 
this assumption, in the context of anti-aging pharmaceutical interventions, is finally revealed by us 
(Figure 3.5). This discrepancy is particularly evident when one compares yeast and mice, the two 
extremes of biological complexity in the considered species. 
Likewise considered common knowledge is the fact that the magnitude of maximum lifespan 
changes is generally more modest than changes in average lifespan. Once again with found 
scientific evidence corroborating empirical knowledge (Figure 3.6). Of unclear importance, we also 
noticed that the distribution of maximum lifespan changes is not as dissimilar across species as 
the distribution of the magnitudes of average/median lifespan effects. 
We shall now take the opportunity to bring attention to a reality: the maximum lifespan effects are 
severely under-reported. There is hardly any excuse for this state of affairs since measuring 
maximum lifespan is free (in a financial sense, as no additional investment has to be made[225]) 
and a panoply of freeware that is already going to be used in the statistical testing of 
median/average lifespan changes has tools dedicated specifically to this end. 
Based on 326 lifespan assays simultaneously reported average and maximum lifespan changes 
and we calculated a highly significant strong linear correlation of around 0.85 (Figure 3.7). The 
fact that, in general, pharmaceutical interventions that prolong average life expectancy extend 
maximum lifespan in a proportional manner is fascinating. 
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Let us recall that some anti-aging intervention, such as physical exercise, extend lifespan but have 
no repercussions on maximum lifespan[226]. This anti-aging profile is attributed (empirically) to a 
reduced rate of incidence of certain mid-life diseases. On the contrary, interventions that increase 
maximum lifespan are ascribed to a slowing down of the “fundamental process of aging”. 
Our results indicate that: or drugs exert their anti-aging effects by simultaneously reducing the rate 
of developing mid-life diseases and targeting the fundamental aging process, or that such 
conceptualizations are irrelevant/artificial in the generality of anti-aging interventions of the 
pharmaceutical type. A practical implication of the high linear correlation between average and 
maximum lifespan changes is that for a high-throughput screen searching for anti-aging chemical 
compounds, either one of the lifespans can be the sole endpoint used without increasing the 
chance of false negatives. 
We proceeded to investigate the possible causal influence of gender on the magnitude of the anti-
aging effects of pharmaceutical interventions. We did so by using two distinct methodologies. 
The first species-centered analysis is especially relevant for biologists that work with M. musculus 
and D. melanogaster. We show that for each of these two species (the only species that we deemed 
to contain enough data points to permit meaningful conclusions) the distribution of 
average/median lifespan changes is not statistically different across genders (Figure 3.8). 
The second analysis aims for a more general view and considers lifespan results from all DrugAge 
species as long as they have a paired assay conducted in the opposite gender (in the exactly same 
experimental conditions). In other words, we sacrifice the accuracy gained by controlling for 
species, in the hopes of increasing our dataset size (and therefore inference power). We were 
successful in our endeavor, as data originated from 11 different species of model organisms 
formed a larger dataset that even allowed us to test the potential role of gender in maximum 
lifespan changes. 
We obtained exceptionally significant linear correlations of approximately 0.88 and 0.90, for the 
magnitude of average and maximum lifespan changes across genders, respectively (Figure 3.9). 
The agreement between the results of the two analyses that discredits the existence of sexual 
dimorphism in the response to anti-aging drugs must not lead to hastily conclude that the same 
applies to humans. It is crucial to remember that humans are unique in this aspect, with one of 
the genders (females) known to have a ubiquitous survival advantage[227]. 
This set of holistic analyses of anti-aging interventions are a new contribution to our field of study, 
and they would not have been possible without DrugAge. 
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The functional statistical enrichment analysis of DrugAge drugs actually consisted in gauging the 
functional enrichment of GO terms of DGIdb genes that interact with DrugAge drugs relative to all 
the genes in the DGIdb database. The enrichment was carried in the ClueGO software because it 
deals with possible interpretability issues by fusing redundant GO terms. At the chosen significance 
threshold (multiple hypotheses corrected mid-p-value < 0.01), we detected 182 enriched GO terms 
from a total of 4830 fused GO terms. As a reference to the reader, the GO term "aging" is 
associated with a corrected mid-p-value of 0.0056. 
Exhaustive inspection of the set of statistically enriched terms allowed us to extract biologically 
meaningful patterns (Table 3.5). 
 
Table 3.5: Conceptual clustering of enriched GO terms and their statistical significance. *p-value is actually multiple hypotheses 
corrected mid-p-value. 
 
 
The hormesis paradigm is severely enriched in the GO terms resulting from the functional 
enrichment of DrugAge, with both xenobiotic and reactive oxygen species related terms. More 
closely it can be observed that all the reactive oxygen species terms significantly enriched belong 
to the positive regulation type, that is, their increase/activation. In other words, all of the opposite 
terms implying a decrease in free radicals abundance, remain insignificant (although being present 
in the universe of possible fused GO terms). Such observation might suggest that for lifespan 
extension, reactive oxygen species should be analyzed from the hormesis paradigm[94], which is 
contrary to the classical view of reactive oxygen species as purely nocive[86]. 
Categories Sub-categories GO term p-value
positive regulation of reactive oxygen species biosynthetic process 5.10E-04
positive regulation of reactive oxygen species metabolic process 2.30E-03
reactive oxygen species biosynthetic process 5.90E-05
regulation of reactive oxygen species biosynthetic process 2.50E-04
reactive oxygen species metabolic process 2.20E-03
regulation of reactive oxygen species metabolic process 4.80E-03
response to xenobiotic stimulus 6.60E-11
xenobiotic metabolic process 7.70E-11
glutathione derivative biosynthetic process 3.40E-14
glutathione metabolic process 4.70E-12
glutathione peroxidase activity 2.90E-08
glutathione binding 6.30E-04
histone deacetylase complex 2.20E-03
NAD-dependent histone deacetylase activity 5.30E-03
histone H3 deacetylation 5.30E-03
sulfur compound metabolic process 7.90E-06
sulfur compound biosynthetic process 2.10E-04
Hormesis
Glutathione
Histone deacetylation
Sulfur compoudns
General ROS terms
Positive ROS regulation
Xenobiotics
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In line with previous works showing that glutathione levels decrease in aged humans[228] and 
manipulations that increase them extend lifespan in flies[229], glutathione-associated terms are 
another strongly enriched process. 
Two other processes are supported by several enriched terms and are known to be implicated in 
aging: histone deacetylation (namely histone H3 deacetylation[230]) and sulfur compound[231] 
involving-processes. 
To examine the possible overlap among genetic and pharmaceutical types of anti-aging 
interventions, we compared the set of human homologs of GenAge lifespan-prolonging genes 
present in DGIdb with DrugAge-interacting DGIdb genes (Figure 3.10). Blaker’s test assigned a p-
value of ͸.ͲʹͶ × ͳͲ−6 for the statistical significance of the overlap between the two lists of genes. 
The results imply that there is a statistically significant number of anti-aging genes that were the 
common target of pharmaceutical and genetic manipulations. While highly statistically significant, 
the overlap is modest in relation to the total number of genes target by either type of interventions. 
We speculate that experts on one kind of interventions should benefit from seeking inspiration from 
colleagues specialized in the other type of manipulations. Interdisciplinarity holds untapped 
potential regarding candidate anti-aging therapies. 
Setting ourselves for screening large libraries of chemical compounds in the search for candidate 
anti-aging chemicals, we trained and optimized the random forest algorithm in a dataset of drugs 
that are known to successfully or unsuccessfully prolong lifespan in C. elegans. We characterized 
each drug by using molecular descriptors and biological features (GO terms annotated in drug-
interacting genes). The random forest trained on a dataset containing both, biological and 
chemical, types of features obtains a median AUC in a 10-fold cross validation of 0.8 (the highest 
that we were able to achieve) which is sufficient for our purposes (Table 3.4). This trained model 
is the one that we are deploying for predicting the class membership of compounds in large-scale 
drug screens for new candidate anti-aging compounds. 
We must also comment that taking advantage of both kinds of features was preferable to using just 
one, even if fewer data samples are available. Such fact stresses the superiority of interdisciplinary 
research among chemo- and bioinformaticians. 
We are currently finishing a manuscript focused on introducing the DrugAge database to the 
scientific community. The majority of the analyses examined in this section are also included to 
showcase the practical utility of DrugAge. The author of this dissertation is a co-first author in said 
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manuscript (the other co-first author is the person responsible for developing the DrugAge web 
interface). 
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CHAPTER 4: CONCLUSIONS AND FUTURES PERSPECTIVES 
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4.1. CONCLUSIONS 
We have made the case for tackling the imminent social crisis, caused by an aged population, 
through the superior means of translational biogerontology. We demonstrated that pharmaceutical 
interventions are the preferred choice to undertake this endeavor and the only viable option with 
potentially real application in the near-term future. Although the theoretical advantages of this 
paradigm are evident, much is yet to be translated to praxis. Our contributions shorten this gap. 
In chapter 2, we crossed information regarding life-extending genes with the drugs targeting them 
in an effort to use drug repurposing to delay the intrinsic mechanisms of aging. More concretely, 
we mapped the human homologs of lifespan-extending genes of model organisms, which are 
curated by GenAge, to the compounds of a meta-database of drug-gene interactions, DGIdb. Sixteen 
compounds, which interact with nineteen anti-longevity human genes, were determined statistically 
enriched. Two anti-aging drug combinations were then suggested after considering the enriched 
drugs clinical profile and potential redundancy in their targeted genes. 
In Chapter 3, we developed DrugAge and applied the information wherein contained in several 
methodologies. 
DrugAge is a new database of life-extending compounds and drugs in model organisms that 
accurately reflects the current knowledge of pharmacological manipulations of aging. Exploratory 
analyses of DrugAge data suggests that maximum and average lifespan changes are linearly 
correlated in a strong fashion and that gender does not affect them. 
We gained some biological insights from the functional enrichment of DrugAge, namely that anti-
aging drugs should be analyzed through the lens of the hormesis paradigm in detriment of free-
radical damage theories. 
Assuming that GenAge and DrugAge are the best proxies for the scientific knowledge regarding 
genetic and pharmaceutical anti-aging therapies in model organisms, respectively, we strove to 
understand the relation between these two categories of potential anti-aging treatments. The study 
of the possible overlap between human orthologues of GenAge lifespan-prolonging genes present 
in DGIdb and DrugAge-interacting DGIdb genes concluded that there is statistically significant 
overlap, nonetheless very modest in magnitude when this is measured in the relative number of 
overlapping genes. 
In preparation of further advancing the paradigm that biogerontology is the best way to face the 
impending social crisis, we trained and optimized a random forest algorithm for high-throughput in 
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silico screen of drug libraries with the aim of discovering and prioritize new candidate anti-aging 
chemical compounds. The optimal configuration of the algorithm performed at more than sufficient 
level for the intended task and therefore we are fully ready to move to the screening stage (work 
that we are undertaking at the moment). 
In sum, we hope to have accelerated the present and future development of biogerontology as The 
pure science on which translational medicine stands. 
4.2. FUTURES PERSPECTIVES 
Regarding section 2, much still needs to be done. We hope to follow on it by confirming the lifespan-
extending potential of the enriched drugs and suggested drug combinations through lifespan assays 
in model organisms. 
Since we already made full use of the currently available knowledge regarding lifespan-extending 
genes, the only way to improve our bioinformatics approach would be to use more chemicals, in 
other words, use several repositories as the sources of drug-gene interactions. We encourage our 
colleagues to advance our methodology, as the drug repurposing paradigm as the potential to 
accelerate the bench-to-bedside transition by more than a decade. 
Concerning DrugAge, we intend to keep it a first-line resource for biogerontologists. The author, as 
DrugAge’s official curator, vows to keep it up-to-date and is already curating information for the 
next update. 
We envision and encourage cheminformaticians, bioinformaticians, biologists, clinicians and even 
the nutraceutical industry to use DrugAge to create a world with less suffering. 
Any application of machine learning can always be improved upon, and the author has intentions 
to do so in the immediate future. Four straightforward refinements are: to screen and optimize a 
vast library of distinct machine learning algorithms; to create a methodology that weights drugs in 
proportion to the magnitude of their lifespan prolongation effects; to tune a given algorithm 
parameters using meta-algorithms[232] instead of grid search; to set the classification task in the 
Bayesian paradigm, including setting a prior for the class probability membership based on a meta-
review of high-throughput screens for anti-aging compounds. 
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